ID

36158

Description

Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02144272

Link

https://clinicaltrials.gov/show/NCT02144272

Keywords

Versions (1)
  1. 4/18/19 4/18/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

April 18, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Inflammatory Arthritis NCT02144272

English

Eligibility Inflammatory Arthritis NCT02144272

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening.
Description

Sign or Symptom Arthritis Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C3540840
UMLS CUI [1,2]
C0003864
UMLS CUI [1,3]
C0449238
presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms.
Description

Swollen joint count

Data type

boolean

Alias
UMLS CUI [1]
C0451521
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
synthetic disease-modifying antirheumatic drugs dmard use as follows:
Description

Synthetic Disease-Modifying Antirheumatic Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C1883254
any treatment with tofacitinib within 28 days prior to baseline or planned treatment with tofacitinib during the study;
Description

Tofacitinib | Tofacitinib Planned

Data type

boolean

Alias
UMLS CUI [1]
C2930696
UMLS CUI [2,1]
C2930696
UMLS CUI [2,2]
C1301732
treatment with other synthetic dmards (eg, hydroxychloroquine, methothrexate, leflunomide, sulfasalazine, and gold salts) at an unstable dose within 28 days prior to baseline or if the dose of drug is planned to be changed during the study.
Description

Synthetic Disease-Modifying Antirheumatic Drugs Dose Unstable | Synthetic Disease-Modifying Antirheumatic Drugs Change in drug dosage Planned | Hydroxychloroquine | Methotrexate | leflunomide | Sulfasalazine | Gold salt

Data type

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C1883254
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C0443343
UMLS CUI [2,1]
C0242708
UMLS CUI [2,2]
C1883254
UMLS CUI [2,3]
C0420247
UMLS CUI [2,4]
C1301732
UMLS CUI [3]
C0020336
UMLS CUI [4]
C0025677
UMLS CUI [5]
C0063041
UMLS CUI [6]
C0036078
UMLS CUI [7]
C0302210
previous treatment with marketed biologic dmards as follows:
Description

Biologic Disease-Modifying Antirheumatic Drug

Data type

boolean

Alias
UMLS CUI [1]
C4055380
etanercept, adalimumab, or anakinra <4 weeks prior to baseline;
Description

Etanercept | adalimumab | anakinra

Data type

boolean

Alias
UMLS CUI [1]
C0717758
UMLS CUI [2]
C1122087
UMLS CUI [3]
C0245109
infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks prior to baseline;
Description

infliximab | certolizumab pegol | golimumab | abatacept | tocilizumab

Data type

boolean

Alias
UMLS CUI [1]
C0666743
UMLS CUI [2]
C1872109
UMLS CUI [3]
C2353893
UMLS CUI [4]
C1619966
UMLS CUI [5]
C1609165
rituximab <12 months prior to baseline
Description

rituximab

Data type

boolean

Alias
UMLS CUI [1]
C0393022
note: other biologic agents for indications other than an inflammatory arthritis may be allowed after discussion with the sponsor
Description

Exception Indication Arthritis | Biological agents allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C1705847
UMLS CUI [1,2]
C3146298
UMLS CUI [1,3]
C0003864
UMLS CUI [2,1]
C0005515
UMLS CUI [2,2]
C0683607
treatment with >10 mg/day, or unstable dose, of oral prednisone or equivalent within 28 days prior to baseline.
Description

Prednisone Oral U/day | Prednisone Oral Dose Unstable | Prednisone Oral Equivalent U/day | Prednisone Oral Equivalent Dose Unstable

Data type

boolean

Alias
UMLS CUI [1,1]
C3216040
UMLS CUI [1,2]
C0456683
UMLS CUI [2,1]
C3216040
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0443343
UMLS CUI [3,1]
C3216040
UMLS CUI [3,2]
C0205163
UMLS CUI [3,3]
C0456683
UMLS CUI [4,1]
C3216040
UMLS CUI [4,2]
C0205163
UMLS CUI [4,3]
C0178602
UMLS CUI [4,4]
C0443343
confirmed or suspected septic arthritis, crystal arthropathy, systemic lupus erythematosus, reactive arthritis, or certain other rheumatic conditions.
Description

Septic Arthritis | Septic Arthritis Suspected | Crystal Arthropathy | Lupus Erythematosus, Systemic | Arthritis, Reactive | Rheumatic disorder

Data type

boolean

Alias
UMLS CUI [1]
C0003869
UMLS CUI [2,1]
C0003869
UMLS CUI [2,2]
C0750491
UMLS CUI [3]
C0152087
UMLS CUI [4]
C0024141
UMLS CUI [5]
C0085435
UMLS CUI [6]
C3495832
Back to the top of the page

Similar models

Eligibility Inflammatory Arthritis NCT02144272

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Sign or Symptom Arthritis Duration
Item
signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening.
boolean
C3540840 (UMLS CUI [1,1])
C0003864 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
Swollen joint count
Item
presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms.
boolean
C0451521 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Synthetic Disease-Modifying Antirheumatic Drugs
Item
synthetic disease-modifying antirheumatic drugs dmard use as follows:
boolean
C0242708 (UMLS CUI [1,1])
C1883254 (UMLS CUI [1,2])
Tofacitinib | Tofacitinib Planned
Item
any treatment with tofacitinib within 28 days prior to baseline or planned treatment with tofacitinib during the study;
boolean
C2930696 (UMLS CUI [1])
C2930696 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Synthetic Disease-Modifying Antirheumatic Drugs Dose Unstable | Synthetic Disease-Modifying Antirheumatic Drugs Change in drug dosage Planned | Hydroxychloroquine | Methotrexate | leflunomide | Sulfasalazine | Gold salt
Item
treatment with other synthetic dmards (eg, hydroxychloroquine, methothrexate, leflunomide, sulfasalazine, and gold salts) at an unstable dose within 28 days prior to baseline or if the dose of drug is planned to be changed during the study.
boolean
C0242708 (UMLS CUI [1,1])
C1883254 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0443343 (UMLS CUI [1,4])
C0242708 (UMLS CUI [2,1])
C1883254 (UMLS CUI [2,2])
C0420247 (UMLS CUI [2,3])
C1301732 (UMLS CUI [2,4])
C0020336 (UMLS CUI [3])
C0025677 (UMLS CUI [4])
C0063041 (UMLS CUI [5])
C0036078 (UMLS CUI [6])
C0302210 (UMLS CUI [7])
Biologic Disease-Modifying Antirheumatic Drug
Item
previous treatment with marketed biologic dmards as follows:
boolean
C4055380 (UMLS CUI [1])
Etanercept | adalimumab | anakinra
Item
etanercept, adalimumab, or anakinra <4 weeks prior to baseline;
boolean
C0717758 (UMLS CUI [1])
C1122087 (UMLS CUI [2])
C0245109 (UMLS CUI [3])
infliximab | certolizumab pegol | golimumab | abatacept | tocilizumab
Item
infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks prior to baseline;
boolean
C0666743 (UMLS CUI [1])
C1872109 (UMLS CUI [2])
C2353893 (UMLS CUI [3])
C1619966 (UMLS CUI [4])
C1609165 (UMLS CUI [5])
rituximab
Item
rituximab <12 months prior to baseline
boolean
C0393022 (UMLS CUI [1])
Exception Indication Arthritis | Biological agents allowed
Item
note: other biologic agents for indications other than an inflammatory arthritis may be allowed after discussion with the sponsor
boolean
C1705847 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
C0003864 (UMLS CUI [1,3])
C0005515 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
Prednisone Oral U/day | Prednisone Oral Dose Unstable | Prednisone Oral Equivalent U/day | Prednisone Oral Equivalent Dose Unstable
Item
treatment with >10 mg/day, or unstable dose, of oral prednisone or equivalent within 28 days prior to baseline.
boolean
C3216040 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C3216040 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0443343 (UMLS CUI [2,3])
C3216040 (UMLS CUI [3,1])
C0205163 (UMLS CUI [3,2])
C0456683 (UMLS CUI [3,3])
C3216040 (UMLS CUI [4,1])
C0205163 (UMLS CUI [4,2])
C0178602 (UMLS CUI [4,3])
C0443343 (UMLS CUI [4,4])
Septic Arthritis | Septic Arthritis Suspected | Crystal Arthropathy | Lupus Erythematosus, Systemic | Arthritis, Reactive | Rheumatic disorder
Item
confirmed or suspected septic arthritis, crystal arthropathy, systemic lupus erythematosus, reactive arthritis, or certain other rheumatic conditions.
boolean
C0003869 (UMLS CUI [1])
C0003869 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0152087 (UMLS CUI [3])
C0024141 (UMLS CUI [4])
C0085435 (UMLS CUI [5])
C3495832 (UMLS CUI [6])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial